ReviewCurrent drug targets2018
Virulence Factor Targeting of the Bacterial Pathogen Staphylococcus aureus for Vaccine and Therapeutics.
Review in Current drug targets, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 106 citations in OpenAlex.
- Metal Nanoparticle-Reinforced Hydrogels Applied in the Inhibition of Clinical Pathogens: Structural Features, Mechanisms, and Biomedical Prospects.Pharmaceutics · 2026Review
- Reduced efficacy of an anti-toxin vaccine from senescence-driven attenuation of toxin virulence.JCI insight · 2026Article
- Passive immunization through polyclonal antibodies against IsdE showed protective activity in an experimental S.aureus challenge model.Folia microbiologica · 2026Article
- Hijacking the signal: a critical evaluation of quorum sensing inhibitors as a next-generation approach against Staphylococcus aureus.Cell communication and signaling : CCS · 2026Review
- Methicillin-resistantiScience · 2026Review
- Omics Reveals the Antibacterial Mechanism of Dihydromyricetin and Vine Tea Extract AgainstMolecules (Basel, Switzerland) · 2026Article
- A comprehensive review of emerging therapeutic strategies against methicillin-resistantFrontiers in microbiology · 2026Review
- Coevolutionary signals in multiple sequence alignments improve virulence factor prediction with an MSA Transformer.Scientific reports · 2025Article
- Overcoming Immune Evasion inACS infectious diseases · 2025Review
- Antimicrobial susceptibility pattern of Staphylococcus Aureus isolated from clinical specimens at University of Gondar comprehensive specialized referral hospital northwest Ethiopia; a retrospective study.BMC research notes · 2025Article
- Toxic Shock Syndrome Toxin-1 (TSST-1) inToxins · 2025Review
- Potential Natural Inhibitors of MRSA ABC Transporters and MecA Identified Through In Silico Approaches.Microorganisms · 2025Article
- AACS synthetic biology · 2025Article
- Review
- Immunoinformatic prediction to identifyVeterinary world · 2024Article
- [Precision medicine in infectious diseases].Innere Medizin (Heidelberg, Germany) · 2024Review
- GEO dataset mining analysis reveals novelFrontiers in molecular biosciences · 2024Article
- Inhibitory effect of theaflavin-3,3'-digallate can involve its binding to the "stem" domain of α-hemolysin of Staphylococcus aureus.European journal of microbiology & immunology · 2023Article
- Article
- Elucidating the CodY regulon inmSystems · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
backgroundStaphylococcus aureus is a major bacterial pathogen capable of causing a range of infections in humans from gastrointestinal disease, skin and soft tissue infections, to severe outcomes such as sepsis. Staphylococcal infections in humans can be frequent and recurring, with treatments becoming less effective due to the growing persistence of antibiotic resistant S. aureus strains. Due to the prevalence of antibiotic resistance, and the current limitations on antibiotic development, an active and highly promising avenue of research has been to develop strategies to specifically inhibit the activity of virulence factors produced S. aureus as an alternative means to treat disease.
objectiveIn this review we specifically highlight several major virulence factors produced by S. aureus for which recent advances in antivirulence approaches may hold promise as an alternative means to treating diseases caused by this pathogen. Strategies to inhibit virulence factors can range from small molecule inhibitors, to antibodies, to mutant and toxoid forms of the virulence proteins.
conclusionThe major prevalence of antibiotic resistant strains of S. aureus combined with the lack of new antibiotic discoveries highlight the need for vigorous research into alternative strategies to combat diseases caused by this highly successful pathogen. Current efforts to develop specific antivirulence strategies, vaccine approaches, and alternative therapies for treating severe disease caused by S. aureus have the potential to stem the tide against the limitations that we face in the post-antibiotic era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.